[ORGANIZATION]
semaglutide
Featured in 6 tracked stories · first seen
Situations
GLP‑1 market, usage, safety & new guidance
182 clusters · 653 sources · last updated
Latest: Brazil's SUS delays rollout of GLP‑1 weight‑loss drugs
GLP‑1 receptor agonists dominate modern obesity and diabetes therapy, now reaching primary‑care, tele‑health and Medicare, with the market projected near $105 bn by 2030. Safety monitoring confirms a modest alopecia sign
GLP‑1 weight‑loss drugs linked to hair loss
2 clusters · 12 sources · last updated
Latest: Ozempic and Wegovy linked to increased hair loss
A study released on 24 July 2026 examined over 50,000 health records and found that users of the GLP‑1 medications semaglutide (Wegovy) and tirzepatide (Mounjaro) faced a markedly higher risk of alopecia—up to 70 % great
Novo Nordisk obesity portfolio: EU approval, legal fight
94 clusters · 434 sources · last updated
Latest: European Commission approves oral semaglutide pill for obesity treatment
Novo Nordisk’s obesity portfolio continues to expand. The European Commission granted marketing authorisation for the 25 mg oral semaglutide (Wegovy) tablet, the first oral GLP‑1 approved in the EU for adults with BMI ≥
GLP‑1 weight‑loss drug efficacy
2 clusters · 2 sources · last updated
Latest: GLP‑1 weight‑loss injections mainly burn fat, not muscle, in first three months
In late June 2026 an oral GLP‑1 compound, Aleniglipron, reported up to a 12 % reduction in body weight during a phase‑2b trial, indicating strong promise for a non‑injectable obesity treatment. A month later a meta‑anal
GLP‑1 obesity drug progress and cost issues
3 clusters · 7 sources · last updated
Latest: Italy reviews GLP-1 obesity drugs amid cost and access concerns
Early July reports highlighted Eli Lilly's experimental peptide retatrutide, which in trial data showed greater weight loss than existing GLP‑1 medicines such as Ozempic and Wegovy, suggesting a new option for obesity tr